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Initial treatment included beginning or increasing systemic
steroids (69%), continuing calcineurin inhibitors (64%) or
beginning topical treatment (52%). Additional treatment was
added within the ﬁrst 28 days for 31% patients. Median lines
of treatment for the total duration of follow-upwere 1 (range
0-4).
Of the evaluable patients, 63/85 and 56/66 had a clinical
response (CR/PR) at 28 days and at 180 days respectively. 36%
developed recurrence of LA GVHD after a documented CR.
26% developed chronic GVHD after LA GVHD at a median of
169 (range 25-383) days after diagnosis of LA GVHD. Median
number of hospital days in the ﬁrst 6 months after the
diagnosis of LA GVHD was 15 (range 1-120) days. 25% had
discontinued immunosuppressive therapy (IST) at the time
of last follow-up with the median duration of IST being 12.8
(range 6.1-24.7) months after HCT. 9% relapsed and 22% died
with themain causes of death being GVHD, infection ormulti
organ failure. Median failure free survival (FFS) as deﬁned by
absence of relapse, death, addition of new IST or develop-
ment of chronic GVHD was 3.6 months (95% CI: 1.7-6.8)
(Figure). Median overall survival (OS) was 25.3 months. No
patient/transplant or GVHD related factors emerged as sig-
niﬁcant predictors for FFS or OS in univariate analysis.
Conclusions: The overall incidence of LA GVHD is low, but it
is associated with prolonged immunosuppression, poor
failure free and overall survival.490
Phase II Clinical Trial of Etanercept Plus Extracorporeal
Photopheresis GVHD Prophylaxis Following Unrelated
Donor Reduced Intensity Transplant
Carrie L. Kitko 1, Thomas Braun 2, Charles Schuler 3,
Sung Won Choi 1, Gregory Yanik 1, Attaphol Pawarode 4,
John Magenau 4, Austin Taylor 5, James L. M. Ferrara 5,
Daniel R. Couriel 4, John Levine 1. 1 Pediatric Blood and
Marrow Transplant Program, University of Michigan, Ann
Arbor, MI; 2 Biostatistics, University of Michigan, Ann Arbor,
MI; 3 Department of Internal Medicine, University of
Michigan, Ann Arbor, MI; 4 Adult Blood and Marrow
Transplant Program, University of Michigan, Ann Arbor, MI;
5 Hematology/Oncology, Icahn School of Medicine at Mount
Sinai, New York, NY
Introduction: Reduced intensity conditioning (RIC) regi-
mens decrease early toxicity after allogeneic hematopoietic
cell transplant (HCT), but their ultimate success depends
on establishing a graft-versus-tumor effect (GVT). Because
graft-versus-host disease (GVHD) and GVT are tightly linked,Figure 1complete elimination of GVHD may lead to an unintended
increased relapse risk in a RIC setting. Therefore, we tested a
novel GVHD prophylaxis regimen intended to preserve GVT
but minimize GVHD mortality.
Methods: 48 patients undergoing RIC unrelated donor
transplant (URD HCT) enrolled from 2009-2012 on a phase
II trial that added etanercept and extracorporeal photo-
pheresis (ECP) to a standard GVHD prophylaxis of tacroli-
mus and mycophenolate mofetil (MMF). The preferred RIC
was ﬂudarabine 160 mg/m2 + busulfan 6.4-12.8 mg/kg +/-
TBI 200 cGy. GVHD prophylaxis consisted of overlapping
agents as follows: Tacrolimus from d-3 to d56 (then
tapered over 4 months in the absence of acute GVHD),
MMF d0-28, etanercept 25 mg subcutaneously 2x weekly
from d0-56 (16 doses), and ECP beginning on d28. ECP was
given once weekly from d28-70, then every other week
until d100, then monthly until d180 for a total of 12
treatments. Donors were required to match to recipients
for 7-8/8 HLA loci.
Results: The median age of the study patients was 60 yr (18-
71). Donors were 7/8 (n¼14, 29%) or 8/8 (n¼34, 71%)
matched. Patients engrafted at a median of 12d (8-26d). The
12mo post-HCT end points for the entire study cohort were
as follows: overall survival 73% (95% CI 61-87) (Figure 1A),
non-relapse mortality (NRM) 21% (9-32), and relapse of 19%
(8-30). The cumulative incidence of grade II-IV acute GVHD
at d100 and 6mo was 46% (32-60) and 57% (42-71) respec-
tively, and for grade III-IV acute GVHD was 17% (6-27) and
19% (8-30). In an exploratory analysis (Figure 1B), GVHD that
developed after 8 doses of etanercept and at least one ECP
treatment (d28) was signiﬁcantly less lethal than GVHD that
developed before ECP began (6mo NRM 11% vs 40%, 12 mo
21% vs 50%; p¼0.04), which suggests that ECP prophylaxis
may ameliorate GVHD lethality. The possible beneﬁt of pro-
phylactic ECP on GVHD outcomes does not appear to be
related to delayed GVHD onset as NRM did not differ in
control patients diagnosed before or after d28. In 69
contemporaneous control patients with grade 2-4 GVHD,
6mo and 12 mo NRM was 32% and 39% respectively, and
there was no difference between patients that developed
GVHD after or before d28 (6mo 27% vs 36%,12mo 33% vs 44%;
p¼0.57).
Conclusions: Six month (83%) and 1yr survival (73%) was
excellent in older, frequently mismatched URD HCT pa-
tients, even though GVHD incidence was not lowered. An
exploratory analysis suggested that if prophylactic ECP has
beneﬁt, the effect is conﬁned to patients who start ECP
before GVHD develops. Strategies focusing on earlier de-
livery of ECP to URD HCT patients could be explored in
future studies..
